Intravenous immunoglobulin-mediated immunosuppression and the development of an IVIG substitute
- 1 September 2013
- journal article
- review article
- Published by Springer Science and Business Media LLC in Clinical and Experimental Medicine
- Vol. 14 (4), 361-373
- https://doi.org/10.1007/s10238-013-0255-4
Abstract
Immunoglobulins are glycoproteins produced by the cells of the immune system. Their primary function is to protect the body from pathogenic infection. Moreover, a concentrated polyclonal mixture of immunoglobulin G (IgG), the so-called intravenous IgG (IVIG), has been used to treat various chronic and systemic disorders of the immune system. Studies on the effects of IVIG in autoimmune disease models have revealed that IgG Fc fragments confer protection against various autoimmune diseases. The identification of this IgG Fc immunomodulatory component is important for the development of IVIG substitutes. The focus of this review is to introduce one of the Fc regulatory entities and to provide a summary of the current knowledge of the putative general mechanisms underlying IVIG activity in vivo on the basis of these Fc fragments. We also address the recent insights into several approaches for the development of IVIG substitutes.This publication has 105 references indexed in Scilit:
- Capture of influenza by medullary dendritic cells via SIGN-R1 is essential for humoral immunity in draining lymph nodesNature Immunology, 2010
- Intravenous immunoglobulins – understanding properties and mechanismsClinical and Experimental Immunology, 2009
- Intravenous immunoglobulin preparations have no direct effect on B cell proliferation and immunoglobulin productionClinical and Experimental Immunology, 2009
- Nanoparticle-based targeted drug deliveryExperimental and Molecular Pathology, 2009
- Translational Mini-Review Series on B Cell-Directed Therapies: B cell-directed therapy for autoimmune diseasesClinical and Experimental Immunology, 2009
- Impaired inhibitory Fcγ receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathyProceedings of the National Academy of Sciences of the United States of America, 2009
- Sialylated multivalent antigens engage CD22in transand inhibit B cell activationProceedings of the National Academy of Sciences of the United States of America, 2009
- Identification of a receptor required for the anti-inflammatory activity of IVIGProceedings of the National Academy of Sciences of the United States of America, 2008
- Distinct cell-specific control of autoimmunity and infection by FcγRIIbThe Journal of Experimental Medicine, 2008
- Modulation of dendritic cell development by immunoglobulin G in control subjects and multiple sclerosis patientsClinical and Experimental Immunology, 2007